Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...
LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock ...
It is doubtless a positive to see that the MediciNova, Inc. (NASDAQ:MNOV) share price has gained some 45% in the last three months. But will that heal all the wounds inflicted over 5 years of ...
MediciNova (MNOV) was notified by Sanofi (SNY) that the Sanofi/Novartis (NVS) litigation was settled. Accordingly, MediciNova is entitled to ...
MediciNova, Inc. (NASDAQ:MNOV – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday .The stock has a 200-day moving average of $1.50 and traded as high ...
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company ...
Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announced that it is possibly considering an offer for the company. Avi ...
StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a report released on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. MediciNova ...
LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock ...